Hirudoid (Chondroitin Polysulfate)

Hirudoid is a topical medication that contains the active ingredient chondroitin polysulfate, a glycosaminoglycan classified as an antithrombotic and anti‑inflammatory agent. It is marketed in the European Union as a skin‑applied preparation. The product is intended for external use on areas of bruising, swelling, or superficial vein inflammation, and it is not designed for oral or systemic administration. Typical formulations are supplied in cream or gel form for topical application.

Hirudoid is used externally to manage minor vascular and traumatic skin conditions where reduced clot formation and inflammation are desired.

- Bruising (contusions) resulting from blunt trauma. - Superficial thrombophlebitis affecting small veins near the skin surface. - Hematoma formation following injury or surgery. - Post‑traumatic swelling of soft tissues. - Edema related to minor sprains or strains. - Small subcutaneous hemorrhages after venipuncture. The formulation is applied directly to the affected area, where it penetrates the skin to exert local antithrombotic and anti‑inflammatory actions without systemic exposure.

Topical application of Hirudoid may be associated with local skin reactions and, rarely, more serious adverse events.

Common: - Mild skin irritation or redness at the application site. - Itching or mild pruritus. - Dryness or peeling of the treated skin. - Transient burning sensation during application. - Slight swelling or edema at the treated area. - Temporary discoloration (hyperpigmentation) that resolves after discontinuation. - Localized itching that intensifies after repeated applications.

Serious: - Allergic contact dermatitis characterized by extensive rash and swelling. - Severe skin ulceration or necrosis at the site of use. - Systemic hypersensitivity reactions such as urticaria or angioedema (very rare). - Development of systemic coagulation abnormalities (extremely rare).

When using Hirudoid, certain precautions should be observed to minimize the risk of adverse reactions and ensure appropriate use.

- Do not apply to broken skin, open wounds, or mucous membranes. - Avoid use on infected or inflamed areas unrelated to the indicated condition. - Discontinue the product if signs of allergic reaction appear, such as rash or swelling. - Keep the medication out of reach of children and pets. - Store at room temperature, protected from excessive heat and moisture. - Consult a healthcare professional before use during pregnancy, lactation, or in patients with known clotting disorders.

Hirudoid may interact with other topical agents or systemic medications that affect coagulation or skin integrity.

Avoid: - Concurrent use with other topical anticoagulants (e.g., heparin creams) due to additive antithrombotic effect. - Application over areas treated with strong irritants or chemical peels, which can increase skin irritation. - Do not use on sun‑exposed skin that will be subjected to UV therapy, as it may increase photosensitivity.

Use with caution: - Use together with systemic anticoagulants (warfarin, direct oral anticoagulants) – monitor for excessive bruising. - Combine with other anti‑inflammatory topicals (corticosteroid creams) – assess for altered skin healing. - Apply in conjunction with occlusive dressings – may enhance absorption and local effects.